Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Anhedonia and Emotion Processing in MDD
NCT05327699Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Nov 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by Emory University. Primary endpoint: Change in glutamate concentration in the medial prefrontal cortex (mPFC) at 14 days. Started Nov 2022; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05327699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327699.